Pharmaniaga Bhd (XKLS:7081) EBIT: RM130 Mil (TTM As of Mar. 2026)


XKLS:7081 Pharmaniaga Bhd XKLS:7081
46 GF Score
Price RM1.22
GF Value RM0.74
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Pharmaniaga Bhd EBIT?

Pharmaniaga Bhd XKLS:7081 -4.69% 46 EBIT is RM130 Mil as of Mar. 2026. GuruFocus rates XKLS:7081 with a GF Score™ of 46/100 and a GF Value™ of RM0.74 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Pharmaniaga Bhd's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was RM56 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was RM130 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Pharmaniaga Bhd's annualized ROC % for the quarter that ended in Mar. 2026 was 10.08%. Pharmaniaga Bhd's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 24.82%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Pharmaniaga Bhd's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 5.88%.


Pharmaniaga Bhd  (XKLS:7081) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Pharmaniaga Bhd's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=220.068 * ( 1 - 30.64% )/( (1526.189 + 1501.428)/ 2 )
=152.6391648/1513.8085
=10.08 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2246.827 - 867.484 - ( 240.224 - max(0, 1611.087 - 1464.241+240.224))
=1526.189

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2357.398 - 996.832 - ( 217.303 - max(0, 1706.929 - 1566.067+217.303))
=1501.428

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Pharmaniaga Bhd's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=225.968/( ( (602.779 + max(287.486, 0)) + (598.657 + max(331.975, 0)) )/ 2 )
=225.968/( ( 890.265 + 930.632 )/ 2 )
=225.968/910.4485
=24.82 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(324.546 + 729.822 + 150.18) - (867.484 + 0 + 49.578)
=287.486

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(672.08 + 665.613 + 11.071) - (996.832 + 0 + 19.957)
=331.975

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Pharmaniaga Bhd's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=129.782/2207.303
=5.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmaniaga Bhd EBIT Related Terms


Pharmaniaga Bhd EBIT Historical Data

* Premium members only.

The historical data trend for Pharmaniaga Bhd's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmaniaga Bhd EBIT Chart

Pharmaniaga Bhd Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 310.40 -570.55 -16.32 266.15 136.08

Pharmaniaga Bhd Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.79 24.68 25.00 23.61 56.49

XKLS:7081 vs MCK, CAH, COR: EBIT Comparison

For the Medical Distribution subindustry, Pharmaniaga Bhd's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmaniaga Bhd EV-to-EBIT vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Pharmaniaga Bhd's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Pharmaniaga Bhd's EV-to-EBIT falls into.


XKLS:7081
46GF Score
Pharmaniaga Bhd XKLS:7081
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmaniaga Bhd EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM130 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of RM130 Mil mean?
Pharmaniaga Bhd (XKLS:7081) has a EBIT of RM130 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Pharmaniaga Bhd.
Is Pharmaniaga Bhd's EBIT too high?
Pharmaniaga Bhd's current EBIT is RM130 Mil. Overall, Pharmaniaga Bhd has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmaniaga Bhd's EBIT compare to MCK and CAH?
Pharmaniaga Bhd's EBIT of RM130 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Distribution company?
A good EBIT depends on the Medical Distribution industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Pharmaniaga Bhd. Pharmaniaga Bhd's current EBIT is RM130 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaniaga Bhd stock overvalued right now?
Based on GuruFocus' analysis, Pharmaniaga Bhd (XKLS:7081) is currently considered Significantly Overvalued. The stock's GF Value™ is RM0.74, compared to a current price of RM1.22 — trading 64.9% above its estimated fair value. The current EBIT is RM130 Mil. Pharmaniaga Bhd's overall GF Score™ is 46/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Pharmaniaga Bhd (XKLS:7081), the current EBIT is RM130 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmaniaga Bhd (XKLS:7081) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmaniaga Bhd stock appears to be overvalued. The current stock price of RM1.22 is trading 64.9% above its estimated GF Value™ of RM0.74. GuruFocus considers Pharmaniaga Bhd to be Significantly Overvalued.

Key valuation signals for XKLS:7081:

  • EBIT: RM130 Mil
  • GF Value™: RM0.74 vs. price of RM1.22 (64.9% above fair value)
  • GF Score™: 46/100 with 8 warning signs

No single metric tells the full story. See the XKLS:7081 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharmaniaga Bhd Business Description

Address No. 7, Lorong Keluli 1B, Kawasan Perindustrian Bukit Raja, Seksyen 7, Selatan, Shah Alam, SGR, MYS, 40000
Pharmaniaga Bhd is engaged in the manufacture of pharmaceuticals and medical devices. The company is also involved in logistics and distribution. The group operates in three segments - Logistics and distribution, Manufacturing in Malaysia, and Manufacturing and distribution in Indonesia. Maximum revenue is generated by the logistics and distribution segment in Malaysia. The Logistics and distribution segment is engaged in distribution, trading and wholesaling of pharmaceutical and medical products as well as supply and installation of medical and hospital equipment in Malaysia.
46GF Score

Get the complete analysis for XKLS:7081

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

RM1.22
Price
RM0.74
GF Value